Açıklama

Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.

Figure 11

Source Paper

Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.

Pharmaceutics (2022)

PMID: 35335987

DOI: 10.3390/pharmaceutics14030612

Cite This Figure

![Figure 11: Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.]()

> Source: Talagavadi Channaiah Anudeep et al. "Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.." *Pharmaceutics*, 2022. PMID: [35335987](https://pubmed.ncbi.nlm.nih.gov/35335987/)

<figure>
  <img src="" alt="Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes." />
  <figcaption>Figure 11. Safety profile data for regenerative cellular therapies in alopecia clinical trials, documenting adverse events and tolerability outcomes.<br>  Source: Talagavadi Channaiah Anudeep et al. "Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.." <em>Pharmaceutics</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35335987/">35335987</a></figcaption>
</figure>

İlgili Kanıtlar

Minoxidil için Androgenetik Alopesi

Derece A · 299 çalışma

Finasteride için Androgenetik Alopesi

Derece A · 206 çalışma

PRP Tedavisi için Alopecia Areata

Derece A · 89 çalışma

Minoxidil için Alopecia Areata

Derece A · 122 çalışma

PRP Tedavisi için Androgenetik Alopesi

Derece A · 144 çalışma